Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06338267 · ClinicalTrials.gov registry record
Validating Innovative Biosensors for Rett Autonomic Symptom Tracking
A clinical trial of Rett Syndrome, sponsored by Rett Syndrome Research Trust.
- Recruiting
- Registry status
- 30
- Enrollment target
- 3
- Study locations
NCT06338267: Recruiting study of Rett Syndrome, sponsored by Rett Syndrome Research Trust.
NCT06338267 is a study of Rett Syndrome that is actively recruiting participants, run by Rett Syndrome Research Trust. The registered enrollment target is 30 participants, below the 524-participant average among 18 other Rett Syndrome trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06338267, a study of Rett Syndrome, is actively recruiting participants, sponsored by Rett Syndrome Research Trust.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients with Rett syndrome for up to 9 weeks. Symptoms of interest include heart rate, breathing, sleep, blood oxygen levels, and movement. Participants will use the biosensors intermittently at home, document device use and symptom status, and will come to the clinic for 1 overnight sleep study. A cohort of up to 10 participants receiving an intervention in a separate clinical trial may also enroll and participate on a custom device schedule for up to 1 year. The study will provide information on the feasibility and ease of use for families at home, biosensor data will be compared to data collected at the same time from the overnight sleep study to demonstrate how well they work in individuals with Rett syndrome, and Emerald will be developed to include movement as a measurable symptom.
Primary Outcome
Use FDA-cleared Vivalink VV330 patch to directly and objectively measure heart rate parameters
Conditions Studied
Study Locations (3)
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-03 |
| Est. Completion | 2026-06 |
What NCT06338267 shows while recruiting
NCT06338267 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 524-participant average among 18 other Rett Syndrome trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT06338267 reports a single indexed study location in Illinois, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT06338267 about?
NCT06338267 is a clinical study titled "Validating Innovative Biosensors for Rett Autonomic Symptom Tracking". The VIBRANT study aims to validate biosensors to objectively and directly measure symptoms in Rett syndrome and create confidence in the use of these devices in clinical trials. VIBRANT will use several FDA-cleared wearable biosensors and a non-wearable device to collect symptom data from patients w...
What is the current status of trial NCT06338267?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-03-03. Estimated completion is 2026-06.
What conditions does trial NCT06338267 study?
This clinical trial studies the following conditions: Rett Syndrome.
Who is sponsoring clinical trial NCT06338267?
This trial is sponsored by Rett Syndrome Research Trust, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06338267 being conducted?
This trial has 3 study locations across Illinois, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rett Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06338267's enrollment target sits among peer trials
30 12th of 18 higher than 7 of 18 other Rett Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rett Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rett Syndrome Registry
RECRUITING
-
Cognitive Function in Rett Syndrome During Trofinetide Treatment
RECRUITING
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
Measuring Impact of Computer Gaming on Arm Use in Rett Syndrome
RECRUITING · NA
-
The Rett Syndrome Global Registry
RECRUITING
-
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI